Research ExplorerPublicationsLow-Grade Hepatic Steatosis Is Associated with Long-term Rem...

Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery

Standard

Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery. / Lautenbach, Anne; Wernecke, Marie; Mann, Oliver; Wagner, Jonas; Wolter, Stefan; Stoll, Fabian; Aberle, Jens.

In: OBES SURG, Vol. 33, No. 2, 02.2023, p. 530-538.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lautenbach, A, Wernecke, M, Mann, O, Wagner, J, Wolter, S, Stoll, F & Aberle, J 2023, 'Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery', OBES SURG, vol. 33, no. 2, pp. 530-538. https://doi.org/10.1007/s11695-022-06406-0

APA

Lautenbach, A., Wernecke, M., Mann, O., Wagner, J., Wolter, S., Stoll, F., & Aberle, J. (2023). Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery. OBES SURG, 33(2), 530-538. https://doi.org/10.1007/s11695-022-06406-0

Vancouver

Lautenbach A, Wernecke M, Mann O, Wagner J, Wolter S, Stoll F et al. Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery. OBES SURG. 2023 Feb;33(2):530-538. https://doi.org/10.1007/s11695-022-06406-0

Bibtex

@article{20629fac67594784888206dafa57f4e3,
title = "Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery",
abstract = "BACKGROUND: Bariatric-metabolic surgery (BS) decreases the grade of steatosis, hepatic inflammation, and fibrosis in patients with severe obesity and non-alcoholic fatty liver disease (NAFLD). Mechanisms include substantial weight loss, but also simultaneous effects on glucose homeostasis. Therefore, we aimed to investigate the association between NAFLD and remission of type 2 diabetes (T2D) up to 8 years following different types of BS.METHODS: In a retrospective cohort study including 107 patients with obesity and T2D at baseline, the association between biopsy-proven NAFLD defined as steatosis in > 5% of hepatocytes at the time of surgery and T2D remission up to 8 years following different surgical procedures was investigated. Univariate regression analysis was used to examine the association between NAFLD and remission of T2D.RESULTS: Long-term remission of T2D was present in 56% of patients (n = 60). The presence of low-grade liver steatosis (grade 1) was associated with remission of T2D. Patients with a liver steatosis score ≥ 2 showed higher HbA1c levels at baseline. There were no significant differences in preoperative presence of lobular inflammation, hepatocyte ballooning, or fibrosis between patients who achieved T2D remission compared with those with no remission. Type of surgery did not affect remission of T2D.CONCLUSION: Our results suggest that the presence of low-grade liver steatosis is associated with remission of T2D following sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). Therefore, BS should be considered at an early NAFLD stage in patients with T2D.",
keywords = "Humans, Obesity, Morbid/surgery, Diabetes Mellitus, Type 2/complications, Non-alcoholic Fatty Liver Disease/complications, Retrospective Studies, Gastric Bypass/methods, Bariatric Surgery, Obesity/surgery, Gastrectomy/methods, Inflammation/complications, Fibrosis, Treatment Outcome",
author = "Anne Lautenbach and Marie Wernecke and Oliver Mann and Jonas Wagner and Stefan Wolter and Fabian Stoll and Jens Aberle",
note = "{\textcopyright} 2022. The Author(s).",
year = "2023",
month = feb,
doi = "10.1007/s11695-022-06406-0",
language = "English",
volume = "33",
pages = "530--538",
journal = "OBES SURG",
issn = "0960-8923",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery

AU - Lautenbach, Anne

AU - Wernecke, Marie

AU - Mann, Oliver

AU - Wagner, Jonas

AU - Wolter, Stefan

AU - Stoll, Fabian

AU - Aberle, Jens

N1 - © 2022. The Author(s).

PY - 2023/2

Y1 - 2023/2

N2 - BACKGROUND: Bariatric-metabolic surgery (BS) decreases the grade of steatosis, hepatic inflammation, and fibrosis in patients with severe obesity and non-alcoholic fatty liver disease (NAFLD). Mechanisms include substantial weight loss, but also simultaneous effects on glucose homeostasis. Therefore, we aimed to investigate the association between NAFLD and remission of type 2 diabetes (T2D) up to 8 years following different types of BS.METHODS: In a retrospective cohort study including 107 patients with obesity and T2D at baseline, the association between biopsy-proven NAFLD defined as steatosis in > 5% of hepatocytes at the time of surgery and T2D remission up to 8 years following different surgical procedures was investigated. Univariate regression analysis was used to examine the association between NAFLD and remission of T2D.RESULTS: Long-term remission of T2D was present in 56% of patients (n = 60). The presence of low-grade liver steatosis (grade 1) was associated with remission of T2D. Patients with a liver steatosis score ≥ 2 showed higher HbA1c levels at baseline. There were no significant differences in preoperative presence of lobular inflammation, hepatocyte ballooning, or fibrosis between patients who achieved T2D remission compared with those with no remission. Type of surgery did not affect remission of T2D.CONCLUSION: Our results suggest that the presence of low-grade liver steatosis is associated with remission of T2D following sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). Therefore, BS should be considered at an early NAFLD stage in patients with T2D.

AB - BACKGROUND: Bariatric-metabolic surgery (BS) decreases the grade of steatosis, hepatic inflammation, and fibrosis in patients with severe obesity and non-alcoholic fatty liver disease (NAFLD). Mechanisms include substantial weight loss, but also simultaneous effects on glucose homeostasis. Therefore, we aimed to investigate the association between NAFLD and remission of type 2 diabetes (T2D) up to 8 years following different types of BS.METHODS: In a retrospective cohort study including 107 patients with obesity and T2D at baseline, the association between biopsy-proven NAFLD defined as steatosis in > 5% of hepatocytes at the time of surgery and T2D remission up to 8 years following different surgical procedures was investigated. Univariate regression analysis was used to examine the association between NAFLD and remission of T2D.RESULTS: Long-term remission of T2D was present in 56% of patients (n = 60). The presence of low-grade liver steatosis (grade 1) was associated with remission of T2D. Patients with a liver steatosis score ≥ 2 showed higher HbA1c levels at baseline. There were no significant differences in preoperative presence of lobular inflammation, hepatocyte ballooning, or fibrosis between patients who achieved T2D remission compared with those with no remission. Type of surgery did not affect remission of T2D.CONCLUSION: Our results suggest that the presence of low-grade liver steatosis is associated with remission of T2D following sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). Therefore, BS should be considered at an early NAFLD stage in patients with T2D.

KW - Humans

KW - Obesity, Morbid/surgery

KW - Diabetes Mellitus, Type 2/complications

KW - Non-alcoholic Fatty Liver Disease/complications

KW - Retrospective Studies

KW - Gastric Bypass/methods

KW - Bariatric Surgery

KW - Obesity/surgery

KW - Gastrectomy/methods

KW - Inflammation/complications

KW - Fibrosis

KW - Treatment Outcome

U2 - 10.1007/s11695-022-06406-0

DO - 10.1007/s11695-022-06406-0

M3 - SCORING: Journal article

C2 - 36508157

VL - 33

SP - 530

EP - 538

JO - OBES SURG

JF - OBES SURG

SN - 0960-8923

IS - 2

ER -